Nuclear thioredoxin-1 is required to suppress cisplatin-mediated apoptosis of MCF-7 cells

被引:28
作者
Chen, Xiao-Ping [1 ]
Liu, Shou [1 ]
Tang, Wen-Xin [1 ]
Chen, Zheng-Wang [1 ]
机构
[1] Huazhong Univ Technol, Coll Life Sci & Technol, Minist Educ, Key Lab Mol Biophys, Wuhan 430074, Peoples R China
基金
中国国家自然科学基金;
关键词
thioredoxin-1; p53; breast cancer; apoptosis; nucleus; NF-KAPPA-B; TRANSCRIPTION FACTOR; DIRECT ASSOCIATION; REDOX REGULATION; BREAST-CANCER; PATHWAY; EXPRESSION; RESISTANCE; PROTEIN-1; CARCINOMA;
D O I
10.1016/j.bbrc.2007.07.033
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
Different cell line with increased thioredoxin-1 (Trx-1) showed a decreased or increased sensitivity to cell killing by cisplatin. Recently, several studies found that the subcellular localization of Trx-1 is closely associated with its functions. In this study, we explored the association of the nuclear Trx-1 with the cisplatin-mediated apoptosis of breast cancer cells MCF-7. Firstly, we found that higher total Trx-1 accompanied by no change of nuclear Trx-1 can not influence apoptosis induced by cisplatin in MCF-7 cells transferred with Trx-1 cDNA. Secondly, higher nuclear Trx-1 accompanied by no change of total Trx-1 can protect cells from apoptosis induced by cisplatin. Thirdly, high nuclear Trx-1 involves in the cisplatin-resistance in cisplatin-resistive cells. Meanwhile, we found that the mRNA level of p53 is closely correlated with the level of nuclear Trx-1. In summary, we concluded that the nuclear Trx-1 is required to resist apoptosis of MCF-7 cells induced by cisplatin, probably through up-regulating the anti-apoptotic gene, p53. (c) 2007 Published by Elsevier Inc.
引用
收藏
页码:362 / 366
页数:5
相关论文
共 21 条
[1]
Thioredoxin is downstream of Smad7 in a pathway that promotes growth and suppresses cisplatin-induced apoptosis in pancreatic cancer [J].
Arnold, NB ;
Ketterer, K ;
Kleeff, J ;
Friess, H ;
Büchler, MW ;
Korc, M .
CANCER RESEARCH, 2004, 64 (10) :3599-3606
[2]
Cisplatin induces apoptosis in oral squamous carcinoma cells by the mitochondria-mediated but not the NF-κB-suppressed pathway [J].
Azuma, M ;
Tamatani, T ;
Ashida, Y ;
Takashima, R ;
Harada, K ;
Sato, M .
ORAL ONCOLOGY, 2003, 39 (03) :282-289
[3]
DASHNAMOORTHY R, 2005, J BIOL CHEM, V280, P40084
[4]
Role of thioredoxin-1 in apoptosis induction by α-tocopheryl succinate and TNF-related apoptosis-inducing ligand in mesothelioma cells [J].
Freeman, Ruth E. ;
Neuzil, Jiri .
FEBS LETTERS, 2006, 580 (11) :2671-2676
[5]
Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival [J].
Grogan, TM ;
Fenoglio-Prieser, C ;
Zeheb, R ;
Bellamy, W ;
Frutiger, Y ;
Vela, E ;
Stemmerman, G ;
Macdonald, J ;
Richter, L ;
Gallegos, A ;
Powis, G .
HUMAN PATHOLOGY, 2000, 31 (04) :475-481
[6]
Distinct roles of thioredoxin in the cytoplasm and in the nucleus -: A two-step mechanism of redox regulation of transcription factor NF-κB [J].
Hirota, K ;
Murata, M ;
Sachi, Y ;
Nakamura, H ;
Takeuchi, J ;
Mori, K ;
Yodoi, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (39) :27891-27897
[7]
AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1 [J].
Hirota, K ;
Matsui, M ;
Iwata, S ;
Nishiyama, A ;
Mori, K ;
Yodoi, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (08) :3633-3638
[8]
High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer [J].
Kim, SJ ;
Miyoshi, Y ;
Taguchi, T ;
Tamaki, Y ;
Nakamura, H ;
Yodoi, J ;
Kato, K ;
Noguchi, S .
CLINICAL CANCER RESEARCH, 2005, 11 (23) :8425-8430
[9]
NF-κB contributes to 6-hydroxydopainine-induced apoptosis of nigral dopaminergic neurons through p53 [J].
Liang, Zhong-Qin ;
Li, Yun-Lin ;
Zhao, Xi-Lin ;
Han, Rong ;
Wang, Xiaom-Xia ;
Wang, Yumei ;
Chase, Thomas N. ;
Bennett, M. Catherine ;
Qin, Zheng-Hong .
BRAIN RESEARCH, 2007, 1145 :190-203
[10]
Thioredoxin participates in a cell death pathway induced by interferon and retinoid combination [J].
Ma, XR ;
Karra, S ;
Lindner, DJ ;
Hu, JB ;
Reddy, SPM ;
Kimchi, A ;
Yodoi, J ;
Kalvakolanu, DD .
ONCOGENE, 2001, 20 (28) :3703-3715